ERES East Resources Acquisition Company

Two Top 50 International Drug Developers Award $3.6 Million in Thorough QT Studies to eResearchTechnology Agreements with Europe-based and Japan-based Pharmaceutical Organizations Demonstrate Global Momentum of Regulatory Guidance PHILADELPHIA, March 31 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has been awarded two Thorough QT studies valued at about $3.6 million in cardiac safety monitoring and services from a Europe-based and a Japan-based international drug developer for two compounds in clinical trials. The awards cover two significant Thorough QT studies, for which eRT is providing comprehensive support, including provision of digital 12-lead ECG equipment designed to facilitate collection of cardiac safety data that is subsequently provided to eRT for analysis. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. "We are delighted to have been selected by the sponsors of these two important trials, which demonstrate the global momentum for implementation of maturing regulatory guidance and the continued trend toward Thorough QT studies with extremely robust ECG collection profiles," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "In one case, the sponsor received value from eRT's Certified Clinical Pharmacology Unit (CPU) Partner Program, which enables eRT and its partners to offer turnkey solutions to drug developers. In the other study, eRT was able to rapidly develop a close working relationship with that sponsor's preferred provider of CPU services." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsors may cancel these agreements at their sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Report on Form 10-K filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden Communications, +1-858-704-5065, for eResearchTechnology Web site: http://www.ert.com/

Copyright